Quester VCT plc Annual General Meeting · process of being sold (IDG) or de-listed (Imagesound) •...
Transcript of Quester VCT plc Annual General Meeting · process of being sold (IDG) or de-listed (Imagesound) •...
18 June 2008
Quester VCT plc
Annual General Meeting
Introduction
Jock Birney, Chairman
Quester VCT: Performance incentive
scheme from merger in 2005
Objective to:
• Achieve exits from long-standing investments
• Resume dividend payments
• Manager incentivised to achieve realisations:
• Fee reduced from 2.5% to 2.0% of net asset value
• Over 4 years, fee of 2.0% (0.5% per annum) payable if cash dividends amount to at least 20% of net asset value at merger
Achievement:
• Realisation proceeds since merger total £23.6m
• Total of dividend payments since the merger (incl. 2.8p recommended final dividend) will amount to 12.2p per share or £14.3million
• Merger NAV was 43.4p per share
• Incentive scheme target is met: incentive fee payable to the manager £1.04 million
Proposed new performance incentive
scheme
• New scheme will reward each year growth in NAV per share in excess of a hurdle return of 5% per annum, starting from base at the 31 December 2007
• Rewards under the scheme will be 20% of the growth in excess of the 5% hurdle
• ‘High-water’ mark will ensure that shareholders only reward incremental growth from year to year
• Escrow account will withhold payment of 1/3rd of the rewards for 24 months, to protect shareholders against subsequent decline in NAV per share
Fund overview & update
Andrew Carruthers, CEO, SPARK Ventures
Agenda
• Tasks performed since appointment as the new manager
• Overview of the year for the fund
• Analysis of valuation movements
• Progress chart
• Company presentation – Isango!
Tasks performed since June 07
Re-shaping of the investment team:
• 4 Quester investment managers have departed after an orderly hand-over, with 2 remaining;
• 4 experienced SPARK investment managers allocated to the portfolio;
• 1 new investment manager brought across from the University funds managed by the group.
Re-allocation and re-evaluation of Portfolio Companies:
• Of the 39 companies in the portfolio, 27 have been reallocated to new managers;
• Whilst relationships with investee company CEO’s has been maintained, every investment has been re-evaluated with ‘fresh eyes’ and old assumptions challenged.
Tasks performed since June 07
(cont.)
Review Findings:
• Many good technologies
• Largely invested too early, with extended commercialization required
• Move into later stage pre-IPO or AIM stocks failed to improve returns
• Difficult decisions have been deferred too long leaving too many investments in the portfolio
We have been busy re-shaping the portfolio with exits, restructurings and new investments
• 6 companies have been closed or substantially written-off
• Other investments have either been sold (Nomad), restructured (HTC), are in the process of being sold (IDG) or de-listed (Imagesound)
• 3 new investments have been made (including Isango), after the year end.
Overview
A few key events have been achieved prior to the change in market sentiment:
• Nomad sale to Metavante Technologies
• Merger between AVANT Immunotherapeutics and Celldex Therapeutics Inc.
Private Equity and Venture markets have since become more risk adverse:
• Underperforming companies cannot raise money (Cluster Seven)
• Exit values are depressed (Antenova)
• Evidence of transactions being cancelled (Elateral)
Life Science investments looking broadly more positive:
• Quoted assets have staged a rally on the back of good news (AVANT, Medigene)
New investment is going into businesses with either revenue or lower capital requirements, or both.
Overview (cont.)
But:
• Profitable exits will usually come last of all
• Even the stronger companies are going to face challenges in the current climate
• Across the industry, exits are taking longer
Analysis of Valuation Movements
Quester VCT plc
Total Venture Capital investments at December 2007 25,634
Less: new Cash Invested (3,764)
Current valuation of investments existing at beginning of financial year 22,985
Valuation of those investments as at February 2007 27,075
Movement (4,090)
Of which: Unquoted Venture Capital investments (1,573)
Quoted Venture Capital investments (2,517)
What has happened to Quoted Venture Capital Valuations since then?
to 31 March 08 (588)
since 31 March 08 (101)
£000’s %
add: valuation of disposals included in the opening balance 1,115
-15%
- 8%
- 40%
Analysis of Valuation Movements (cont.)
62% of the total fall in the valuation of the venture capital portfolio is derived from quoted investments where 3rd parties set the price
i.e. The manager’s judgement is not involved in the revaluation
The £1.6m fall in the value of the unquoted venture capital contains £5.6m of write-downs, partially offset by a £4m gain
• Of the gains, £3.7m are in the form of realized proceeds from the sale of Nomad
• £2.9m of the write-downs come from those investments involved in the hardware or materials sector, which are more capital intensive and suffer more competition from emerging markets
Progress update since June 2007
Exits / liquidityEmerging success
Good progressStill early stage
ConcernsFailures
Arithmatica
Artisan
Comm Internet
HTC Healthcare
Int’l Diagnostics
Haemostatix
Secerno
Teraview
Vivacta
We7
Antenova
Sift
Uniservity
Avidex (Medigene)
Advanced Valve
Anthropics
Keronite
Pelikon
Celldex
Cluster Seven
Lectus
Level Four
Advanced Valve
Anthropics
Keronite
Pelikon
Perpetuum
Nomad
Elateral
Nomad
Workshare Workshare
Celldex/AVANT
Perpetuum
Elateral
Oxford Immunotec Oxford Immunotec
Cluster Seven
Lectus
Level Four
Isango!
Ranjan Singh, Chairman
18 June 2008
Quester VCT plc
Annual General Meeting
Resolution 1
Annual report & accounts
Resolution 1 – Proxy votes
For 5,917,157
Including Chairman’s discretion
Against 22,806
Resolution 2
Directors remuneration report
Resolution 2 – Proxy votes
For 5,338,567
Including Chairman’s discretion
Against 494,049
Resolution 3
Declaration of a final dividend of 2.8p per share
Resolution 3 – Proxy votes
For 5,217,629
Including Chairman’s discretion
Against 630,730
Resolution 4
Re-election of JD Birney as a Director
Resolution 4 – Proxy votes
For 5,267,223
Including Chairman’s discretion
Against 497,193
Resolution 5
Election of A B Carruthers as a Director
Resolution 5 – Proxy votes
For 5,450,752
Including Chairman’s discretion
Against 337,158
Resolution 6
Re-election of TP Sooke as a Director
Resolution 6 – Proxy votes
For 5,250,239
Including Chairman’s discretion
Against 460,358
Resolution 7
Re-appointment of Grant Thornton UK LLP as auditors
Resolution 7 – Proxy votes
For 5,808,559
Including Chairman’s discretion
Against 113,686
Resolution 8
Authority to allot shares
Resolution 8 – Proxy votes
For 5,739,479
Including Chairman’s discretion
Against 159,590
Resolution 9
Authority for the disapplication of pre-emption rights
Resolution 9 – Proxy votes
For 5,629,374
Including Chairman’s discretion
Against 230,476
Resolution 10
Authority to change the company name to SPARK VCT plc
Resolution 10 – Proxy votes
For 5,223,345
Including Chairman’s discretion
Against 692,685
Resolution 11
Authority for the company to purchase its own shares
Resolution 11 – Proxy votes
For 5,682,215
Including Chairman’s discretion
Against 265,730
Resolution 12
Adoption of new Articles of Association
Resolution 12 – Proxy votes
For 5,616,994
Including Chairman’s discretion
Against 140,103
18 June 2008
Quester VCT plc
Annual General Meeting
Vivacta
Medical diagnostics; point-of-care tests
• Good technical progress
• Thyroid function to be first product
• Market prototypes expected Sept 2008
• Discussions with potential licensees
• Funded to Q4 09
Biological drug treatments for cancer and auto-immune diseases
Solid progress in recent months:
• Good news from clinical trial of its pancreatic cancer treatment
• Market rumours of a bid from Pfizer
• Reflected in price rise to ~ €6 level
We have sold one third of our holding at this price
Upside remains, including positive news anticipated from the original Avidex technologies
Further price rise in recent days
(ex-Avidex)
Ion channel drug discovery and development
• Serious problems encountered with both lead programmes
• Licensing deal with pharma Partner delayed by partner’s internal reorganisation
• Bridge financing of up to £2.2m sought to finance company to trade sale in 18 months
• Declined to participate
Proposed plan has unrealistic targets
Poor management, ineffectual chairman
Not listening to corporate investors
• Decisive action taken to minimise losses
Developing artificial platelets to treat clotting defects
• Making good technical progress
• Closed internal round of £0.9m at modest uplift in price in April.
• New CEO Ben Nichols in post and bringing BDM skills to bear
• Chairman Robert Burns (ex-CEO of Celldex) appointed.
• Still early stage, but building out phase under way